Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Enteral nutrition is mainly used for preoperative feeding of patients with anorexia and related diseases, including mechanical gastrointestinal dysfunction, critical illness and malnutrition. It was developed by Fresenius Kabi and was China in 1995. Chinese market. By 2020, in addition to Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd., there are Fresenius Kabi Deutschland GmbH, Fresenius Kabi Huarui Pharmaceutical Co., Ltd., Abbott Laboratories BV, and Milupa GmnH & Co KG and other 8 manufacturers in China’s Enteral Nutrition market.
According to CRI analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019. In 2020, due to the impact of the COVID-19 epidemic on the hospital's overall diagnosis and treatment services, the sales value of Enteral Nutrition in China fell slightly, reached CNY1.155 billion in 2020. The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.
CRI expects that with the effective relief of the COVID-19 epidemic, the sales of Enteral Nutrition in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Enteral Nutrition is widely used clinically. With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.
Topics Covered:
-The impact of COVID-19 on China's Enteral Nutrition market
- Sales value of China's Enteral Nutrition 2016-2020
- Competitive landscape of China's Enteral Nutrition market
- Prices of Enteral Nutrition in China
- Prices of Enteral Nutrition in China by regions and manufacturers
- Analysis on factors affecting the development of China's Enteral Nutrition market
- Prospect of China's Enteral Nutrition market from 2021 to 2025
According to CRI analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019. In 2020, due to the impact of the COVID-19 epidemic on the hospital's overall diagnosis and treatment services, the sales value of Enteral Nutrition in China fell slightly, reached CNY1.155 billion in 2020. The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.
CRI expects that with the effective relief of the COVID-19 epidemic, the sales of Enteral Nutrition in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Enteral Nutrition is widely used clinically. With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.
Topics Covered:
-The impact of COVID-19 on China's Enteral Nutrition market
- Sales value of China's Enteral Nutrition 2016-2020
- Competitive landscape of China's Enteral Nutrition market
- Prices of Enteral Nutrition in China
- Prices of Enteral Nutrition in China by regions and manufacturers
- Analysis on factors affecting the development of China's Enteral Nutrition market
- Prospect of China's Enteral Nutrition market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
